Jump to content

Mocetinostat

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DePiep (talk | contribs) at 18:17, 7 July 2015 (Chembox: rm/replace deprecated params. Fix unknown parameters (via AWB script)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Mocetinostat
Names
IUPAC name
N-(2-Aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl] benzamide
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
UNII
  • InChI=1S/C23H20N6O/c24-19-5-1-2-6-21(19)28-22(30)17-9-7-16(8-10-17)14-27-23-26-13-11-20(29-23)18-4-3-12-25-15-18/h1-13,15H,14,24H2,(H,28,30)(H,26,27,29) ☒N
    Key: HRNLUBSXIHFDHP-UHFFFAOYSA-N ☒N
  • InChI=1/C23H20N6O/c24-19-5-1-2-6-21(19)28-22(30)17-9-7-16(8-10-17)14-27-23-26-13-11-20(29-23)18-4-3-12-25-15-18/h1-13,15H,14,24H2,(H,28,30)(H,26,27,29)
    Key: HRNLUBSXIHFDHP-UHFFFAOYAW
  • C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC3=NC=CC(=N3)C4=CN=CC=C4
Properties
C23H20N6O
Molar mass 396.454 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers including follicular lymphoma, Hodgkin's lymphoma and acute myelogenous leukemia.[1][2][3]

One clinical trial (for refractory follicular lymphoma) was temporarily put on hold due to cardiac problems but resumed recruiting in 2009.[4]

In 2010 favourable results were announced from the phase II trial for Hodgkin's lymphoma.[5]

MGCD0103 has also been used as a research reagent where blockage of members of the HDAC-family of histone deacetylases is required.[6]

Mechanism of action

It works by inhibiting mainly histone deacetylase 1 (HDAC1), but also HDAC2, HDAC3, and HDAC11.[7]

References

  1. ^ "Pharmion Corporation (PHRM) Release: Clinical Data On Oncology HDAC Inhibitor MGCD0103, Presented At The American Society of Clinical Oncology 42nd Annual Meeting" (Press release). Colorado, United States: BioSpace. June 6, 2006. {{cite press release}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  2. ^ Gelmon, K.; Tolcher, A.; Carducci, M.; Reid, G. K.; Li, Z.; Kalita, A.; Callejas, V.; Longstreth, J.; Besterman, J. M.; Siu, L. L. (2005). Phase I trials of the oral histone deacetylase (HDAC) inhibitor MGCD0103 given either daily or 3x weekly for 14 days every 3 weeks in patients (pts) with advanced solid tumors. 2005 ASCO Annual Meeting. J. Clin. Oncol. Vol. 23, no. 16S. 3147.
  3. ^ MethylGene to Resume Development of its HDAC Inhibitor, MGCD0103 (Mocetinostat), Sept 2009
  4. ^ "METHYLGENE TO RESUME DEVELOPMENT OF ITS HDAC INHIBITOR, MGCD0103 (MOCETINOSTAT)". 21 Sep 2009.
  5. ^ "Final Phase 2 Clinical Data for Mocetinostat (MGCD0103) in Relapsed/Refractory Hodgkin Lymphoma Patients". 6 Dec 2010.
  6. ^ Pfefferli, Catherine; Müller, Fritz; Ja¿wi¿ska, Anna; Wicky, Chantal (2014). "Specific NuRD components are required for fin regeneration in zebrafish". BMC Biol. 12 (30): 30. doi:10.1186/1741-7007-12-30. PMC 4038851. PMID 24779377.{{cite journal}}: CS1 maint: unflagged free DOI (link)Open access icon
  7. ^ MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo
Retrieved from "https://en.wikipedia.org/w/index.php?title=Mocetinostat&oldid=670397461"